What is Calcium dobesilate used for?

Calcium dobesilate is evaluated for the following indications with varying evidence strength: Chronic venous insufficiency (evidence tier D), Diabetic retinopathy (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Calcium dobesilate?

Common side effects of Calcium dobesilate (≥ 1 in 100): Nausea, Epigastric pain, Diarrhea, Skin rash. See the Safety section for uncommon and serious reactions.

Who should not take Calcium dobesilate?

Calcium dobesilate is contraindicated in: Calcium dobesilate hypersensitivity; Pregnancy in T1. Full list in the Safety section.

Used symptomatically for leg heaviness, edema, and pain in chronic venous insufficiency CEAP classes C0s–C3. Evidence is weak: the 2020 Cochrane meta-analysis of flavonoid and non-flavonoid venoactive agents reported moderate effect on pain and edema with low certainty. No benefit on hard outcomes (venous ulcer healing, disease progression) has been described. ESVS 2022 international guidance does not place this drug among first-line agents – the base treatment is compression and lifestyle change.

Sources

Diabetic retinopathy

Not recommended

Historically used in non-proliferative diabetic retinopathy in Spain, Eastern Europe, and Latin America. No evidence base: the 2017 Cochrane review of calcium dobesilate in diabetic retinopathy showed no clinically meaningful effect on disease progression or visual preservation. ICO 2017 and 2024 do not list it among preferred agents. Foundation therapy for diabetic retinopathy: glycemic, blood pressure, and lipid optimization; for proliferative disease and macular edema – laser photocoagulation, intravitreal anti-VEGF (ranibizumab, aflibercept, bevacizumab).

Sources

Evidence

Evidence for calcium dobesilate on hard clinical outcomes in CVI and diabetic retinopathy is limited. Use is justified only as short-term symptomatic adjunct to foundation therapy (compression in CVI, glycemic control in retinopathy); no disease modification should be expected. With persistent complaints, reconsider diagnosis and base therapy rather than escalating venoactive doses.

Contraindications

Calcium dobesilate hypersensitivity
Pregnancy in T1

Serious adverse effects

Agranulocytosis (rare, isolated cases – EMA issued a 2014 warning)
Allergic reactions

Common adverse effects

Nausea
Epigastric pain
Diarrhea
Skin rash

PregnancyFDA C

Avoid in T1 where possible due to limited data. For pregnancy venous symptoms, class 2 compression stockings are first-line.

Breastfeeding

Limited data. Use during lactation only when clearly indicated.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Calcium dobesilate

Mechanism of action

Indications

Chronic venous insufficiency

Marketing claims without evidence base

Diabetic retinopathy

Practical notes

Evidence

Check interaction with another drug

Official sources

Safety